Protodioscin

Other Names

(3β,22α,25R)-26-(β-D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-glucopyranoside26-O-β-D-glucopyranosyl-22-hydroxyfurost-5-ene-3β,26-diol-3-O-β-D-diglucorhamnosideFurostanol INSC 698796PROTODIOSONSaponin CSHENGMATING[(22R,25R)-22-Hydroxy-26-(β-D-glucopyranosyloxy)furosta-5-ene-3β-yl]2-O,4-O-bis(α-L-rhamnopyranosyl)-β-D-glucopyranoside[(25R)-26-(β-D-Glucopyranosyloxy)-22α-hydroxyfurost-5-en-3β-yl]2-O,4-O-bis(α-L-rhamnopyranosyl)-β-D-glucopyranoside

Synopsis

Protodioscin: A Comprehensive Reference

1. Identity: Chemical Name, Botanical Sources, and Forms

1.1 Chemical Identity

Protodioscin is a naturally occurring steroidal saponin classified as a furostanol glycoside, with the molecular formula C₅₁H₈₄O₂₂, found in various plant species including Tribulus terrestris, Dioscorea species (such as Dioscorea nipponica and Dioscorea collettii), fenugreek (Trigonella foenum-graecum), and Trillium govanianum. Chemically, protodioscin features a furostanol aglycone backbone linked to a trisaccharide chain at the 3-OH position and a glucose monosaccharide at the 26-OH group, distinguishing it from related compounds like dioscin and methylprotodioscin.

Unlike dioscin, which bears the E and F ring closure of the spirostanol skeleton, protodioscin lacks ring F, leaving the side chain open — a structural feature that classifies it as a furostanol saponin. Acid hydrolysis of this bisdesmoside produces diosgenin, a phytoestrogen that can be chemically converted into progesterone. Protodioscin is a natural molecule belonging to the class of steroid saponins, mainly produced by monocotyledons.

Protodioscin is defined as a furostanol steroidal saponin primarily found in the Dioscoreaceae family that can induce apoptosis in tumor cells and inhibit tumor glycolysis through various mechanisms, including the activation of apoptosis-regulating proteins and the generation of reactive oxygen species.

1.2 Botanical Sources and Geographic Distribution

Protodioscin is a steroidal saponin compound found in a number of plant species, most notably in the Tribulus, Trigonella, Dioscorea, and Trillium families. It is best known as the putative active component of the herbal aphrodisiac plant Tribulus terrestris.

Tribulus terrestris is native to warm temperate and tropical regions worldwide, including the Mediterranean basin, Asia, and Australia, and has become widely distributed in drier temperate areas globally. In traditional medicine, it is a major bioactive constituent in Tribulus terrestris, where its concentration can reach up to 1,530 mg/100 g in aerial parts, varying by plant part, geographic origin, and extraction method.

Samples of T. terrestris collected in Bulgaria, Greece, Serbia, Macedonia, Turkey, Georgia, Iran, Vietnam, and India have been analyzed for the presence and concentration of protodioscin and other saponins, with results revealing distinct differences in content depending on the region of sample collection, plant part studied, and stage of plant development. The samples from Bulgaria, Turkey, Greece, Serbia, Macedonia, Georgia, and Iran exhibited a similar chemical profile, with protodioscin and prototribestin as the main components. Concentrations are highest in the aerial parts of T. terrestris, with reported levels up to 1.53% in samples from regions like Bulgaria.

Other notable natural sources include species of the genus Dioscorea, such as Dioscorea villosa, Dioscorea tokoro, Dioscorea nipponica, and Dioscorea collettii, where protodioscin is concentrated in the rhizomes and often co-occurs with related compounds like dioscin and methyl protodioscin.

Among bioactive compounds isolated from fenugreek seeds are protodioscin, trigoneoside, diosgenin, yamogenin, and others. Trigonella foenum-graecum, commonly called fenugreek, is a leguminous plant native to many Asian, Middle Eastern, and European countries; the seeds and leaves of fenugreek are edible and are used as condiments and as Ayurvedic medicine in the Indian subcontinent to treat diabetes, high cholesterol, wounds, inflammation, and gastrointestinal ailments.

1.3 Key Related Compounds and Analogs

Spirostanol and furostanol saponins are considered the most characteristic chemicals in T. terrestris. To date, 108 kinds of steroidal saponins have been isolated from T. terrestris, among them 58 kinds of spirostane saponins and 50 kinds of furostane saponins. The steroidal saponins, such as protodioscin and protogracillin, are thought to confer T. terrestris its unique biological activities.

Additional closely related compounds include methyl protodioscin (MPD) and pseudoprotodioscin (PPD). Methyl protodioscin (MPD), a bioactive natural compound extracted from the rhizome of Dioscorea collettii var. hypoglauca (Dioscoreaceae), has been investigated for its numerous pharmacological activities, including lipid-lowering, anti-inflammatory, and anticancer activities. Enzymatic hydrolysis of protodioscin (a furostanoside) can produce dioscin (a spirostanoside), and further hydrolysis produces progenin III.

1.4 Commercial Preparations and Standardization

Commercial preparations include standardized dry extract tablets — for example, one branded product (Tribestan) contains Tribulus terrestris herba extractum siccum (35–45:1) 250 mg per film-coated tablet, standardized to furostanol saponins (not less than 112.5 mg).

Protodioscin is also extracted from fenugreek seeds as a high-purity furostanolic saponin fraction. Commercial extraction processes have been directed specifically toward extracting one class of saponins — furostanolic saponins, particularly protodioscin — at high purity levels of greater than 70% from seeds of fenugreek. The patented fenugreek extract known commercially as "Furosap" is standardized to contain a minimum of 20% protodioscin. Clinical investigation of Furosap evaluated supplementation of a novel fenugreek seed extract enriched in 20% protodioscin, in capsule doses of 250 mg twice daily, over a period of 12 consecutive weeks.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine

T. terrestris is native to south-eastern and Mediterranean Europe, temperate and tropical Asia and Africa, and northern Australia. The use of T. terrestris from ancient times occurred in the traditional medicine of major cultures in these geographical areas, such as traditional Chinese medicine, traditional Indian medicine (Ayurveda), and the traditional medicine of south-eastern Europe, defining its ethnopharmacological relevance as a medicinal plant.

As a traditional Chinese medicine, it was listed as a top-grade medicine in the earliest extant Chinese pharmaceutical monograph, the Shen Nong Ben Cao Jing. In the Chinese Pharmacopoeia, the fruits of T. terrestris have been used for tonifying the kidneys and as a diuretic and cough expectorant that improves eyesight and for the treatment of skin pruritus, headache and vertigo, and mammary duct blockage.

2.2 Ayurveda (Indian Traditional Medicine)

Tribulus terrestris L. is an important traditional therapeutic plant that has been utilized for multiple purposes since the Vedic period and belongs to the family Zygophyllaceae. It is distributed in subtropical regions including India, China, New Zealand, Sri Lanka, and Pakistan.

In India, the fruits have been used in the treatment of infertility, impotence, erectile dysfunction, and low libido in Ayurveda. In addition, the roots and fruits are considered to have cardiotonic properties.

2.3 Other Traditional Systems

The fruits and roots of T. terrestris have been used as folk medicine for thousands of years in China, India, Sudan, and Pakistan, and the plant has been used for generations to energize, vitalize, and improve sexual function and physical performance in men.

Tribulus terrestris has been traditionally used for centuries in various medical systems, including Ayurveda, traditional Chinese medicine, and folk practices in regions such as India, South Africa, Turkey, and Bulgaria, particularly for managing kidney and urinary tract conditions. In more recent times, athletes in Eastern Europe have turned to T. terrestris to boost physical performance, particularly enhancing muscular strength and stamina.

2.4 Traditional Use of Fenugreek as a Source

Trigonella foenum-graecum (fenugreek) is one of the oldest traditional medicinal plant species originating from the Iran and Mediterranean regions. In ancient Egypt, fenugreek was documented for increasing milk production in lactating women and for other therapeutic purposes. The seeds and leaves of fenugreek are used as condiments and as Ayurvedic medicine in the Indian subcontinent to treat diabetes, high cholesterol, wounds, inflammation, and gastrointestinal ailments.

2.5 Traditional Use of Dioscorea Species

Steroidal saponins derived from Dioscorea plants have attracted increasing attention because of their wide range of applications and pharmacological activities. Among these, Dioscorea spongiosa serves as a traditional Chinese medicine herb widely cultivated in China, with research on its biological effects focused primarily on lowering uric acid, anti-inflammatory and analgesic properties, and anti-osteoporosis effects.

3. Key Phytochemical Constituents and Mechanisms of Action

3.1 Hormonal Pathways

Protodioscin increases the levels of luteinizing hormone (LH), testosterone, dehydroepiandrosterone (DHEA), and dihydrotestosterone (DHT). Although the precise mechanism has not been fully established, protodioscin has been reported to stimulate the release of nitric oxide in corpus cavernosum tissue, as well as to significantly increase circulating levels of testosterone, dihydrotestosterone, and dehydroepiandrosterone in animal models.

Protodioscin is thought to contribute to increased androgen receptor immunoreactivity in some tissues, likely as a secondary effect of elevated levels of endogenous androgens such as testosterone and dihydrotestosterone (DHT).

Aphrodisiac effects may be associated with the constituent protodioscin, which leads to an increase in some sex hormones. Erectogenic effects may also occur via conversion of protodioscin to DHEA, or by concentration-dependent relaxation of the corpus cavernosum via reactions in the nitric oxide (NO)/NO synthase pathway and corpus cavernosum endothelium. The NO release effect may explain observed physiological responses to tribulus supplementation, independent of testosterone level.

3.2 Nitric Oxide and Vascular Mechanisms

Gauthaman et al. have reported that protodioscin is involved in the nitric oxide synthase pathway determining relaxation of the corpus cavernosum. This mechanism parallels the pathway through which phosphodiesterase-5 inhibitors operate, though protodioscin acts upstream through NO release rather than by blocking cGMP degradation.

3.3 Anticancer Mechanisms

Protodioscin (PD), a natural steroidal saponin extracted from Dioscorea and Tribulus terrestris, has been shown to exhibit anticancer, antimetastatic, and pro-autophagic and apoptotic activities in various malignant tumor cells. In preclinical models, PD induced apoptosis, loss of mitochondrial membrane potential, and endoplasmic reticulum expansion in hepatocellular carcinoma (HCC) cells. Downregulation of Mfn1 or Bak reversed PD-induced apoptosis and loss of mitochondrial membrane potential.

In the context of pancreatic cancer, methyl protodioscin (a close structural analog) inhibited proliferation and promoted apoptosis of pancreatic cancer cells. Results demonstrated that MPD decreased oncogene c-Myc at the protein level and resulted in concomitant reduction in glycolysis. In vivo assays with xenograft mouse models further confirmed these in vitro observations.

3.4 Anti-Hyperlipidemic Mechanisms

A bioactive phytochemical, protodioscin, isolated from the rhizomes of Dioscorea nipponica, was identified for its anti-hyperlipidemic effect. In hyperlipidemic rats, post-administration of protodioscin significantly reduced the time of blood coagulation. In addition, the blood levels of triglyceride, cholesterol, and low- and high-density lipoproteins were also changed accordingly. This was described as the first report of an antihyperlipidemic effect of protodioscin.

3.5 Relationship with Diosgenin (the Aglycone)

Acid hydrolysis of protodioscin (a bisdesmoside) produces diosgenin, a phytoestrogen that can be chemically converted into progesterone. Diosgenin is found in a variety of plants, including fenugreek and the roots of wild yam. Much of protodioscin's biological activity in vivo may be attributable in part to its conversion to diosgenin and downstream steroid intermediates after gastrointestinal hydrolysis.

3.6 Pharmacokinetics and Bioavailability

A study concluded that protodioscin had low bioavailability in vivo as an isolated compound; however, the same group of authors showed that after administration of a Dioscorea extract, the pharmacokinetic profile of protodioscin revealed good bioavailability. Despite multiple in vivo studies with T. terrestris, very little is known about the pharmacokinetics of the therapeutically active compounds.

4. Scientific Evidence by Area of Application

4.1 Male Sexual Function and Erectile Dysfunction

Extracts of T. terrestris standardized for protodioscin content have been shown to produce proerectile effects in isolated tissues and aphrodisiac activity in several animal models. The preponderance of this evidence, however, comes from animal studies rather than rigorously conducted human trials.

Regarding human evidence, a prospective, randomized, double-blind, placebo-controlled clinical trial was conducted. This was a Phase IV, prospective, randomized, double-blind, placebo-controlled clinical trial in parallel groups. It included 180 males aged between 18 and 65 years with mild or moderate erectile dysfunction (ED) and with or without hypoactive sexual desire disorder (HSDD): 90 were randomized to T. terrestris (Tribestan) and 90 to placebo. Patients with ED and comorbid hypertension, diabetes mellitus, and metabolic syndrome were included. Each patient received orally 3×2 film-coated tablets daily after meals during the 12-week treatment period, with sexual function including ED assessed by the International Index of Erectile Function (IIEF) Questionnaire. The primary outcome measure was the change in IIEF score after 12 weeks of treatment.

A 2025 systematic review synthesized the available clinical trial evidence: after searching the literature (n = 162), 10 studies were eligible for this review, comprising 9 clinical trials and 1 quasi-experimental study (a study without a control). The Jadad score revealed low methodological quality for 50% of the studies. The studies involved 15 to 172 participants (total = 483) aged between 16 and 70 years with different health conditions, including healthy men. A 2025 meta-analysis of RCTs (total n = 543) reported improvements in International Index of Erectile Function (IIEF) scores for ED (mean difference 3.23 for IIEF-5), but results were inconsistent across studies with small samples (n = 30–172).

In summary, while animal studies consistently demonstrate proerectile and androgenic effects, human clinical evidence is limited by small sample sizes, heterogeneous populations, variable standardization of extracts, and generally low methodological quality. The evidence in men is therefore characterized as preliminary and mixed.

4.2 Female Sexual Dysfunction

A systematic review was performed to assess the effectiveness and safety of Tribulus terrestris to treat female sexual dysfunction (FSD). Unrestricted electronic searches were performed across multiple databases. Any randomized controlled trials (RCTs) comparing T. terrestris versus inactive/active interventions were included. After the selection process, 5 RCTs (n = 279 participants) were included.

After 1 to 3 months of treatment, premenopausal and postmenopausal women randomized to T. terrestris had a significant increase in sexual function scores. Three months of treatment with T. terrestris showed a significant increase in the serum testosterone levels of premenopausal women. The certainty of the evidence was very low, which means that there is very little confidence in the effect estimates, and future studies are likely to change these estimates. More RCTs are needed to support or refute the use of T. terrestris.

A systematic review of five randomized controlled trials (RCTs) involving 279 women with sexual dysfunction found significant improvements in overall sexual function scores, including desire, arousal, lubrication, satisfaction, and pain, after 1–3 months of supplementation (doses 250–750 mg/day), with low certainty of evidence due to methodological limitations.

4.3 Male Infertility and Sperm Parameters

A clinical study using a protodioscin-enriched fenugreek seed extract (Furosap, 20% protodioscin) reported improvements in free testosterone level and sperm profile in healthy volunteers, with extensive blood chemistry analyses revealing broad spectrum safety and the conclusion that the extract is safe and efficacious in boosting serum free testosterone levels, healthy sperm profile, mental alertness, cardiovascular health, and overall performance in male volunteers. This was a small, uncontrolled study and should be interpreted cautiously.

4.4 Athletic Performance and Body Composition

The claim that protodioscin meaningfully improves athletic performance or increases muscle mass in humans is not robustly supported by clinical evidence. Antonio et al. (2000) reported that oral administration of Tribulus at a dose of 3.21 mg/kg body weight had no significant effect on body composition or exercise performance in resistance-trained subjects. A 2021 RCT in 30 male CrossFit athletes (770 mg/day for 6 weeks) showed no changes in body composition despite some hormonal shifts.

Steroidal saponins from T. terrestris, like protodioscin, could theoretically have beneficial effects on physical fitness through improvements on hemoglobin and hematocrit levels. However, this hypothesis has not been definitively confirmed in well-powered human clinical trials.

4.5 Anticancer Activity

The anticancer activities of methyl protodioscin have been tested by the National Cancer Institute's anticancer drug discovery screen with a panel of 60 human cancer cell lines, and it was reported that MPD had distinct cytotoxic activity and led to G2/M arrest and apoptosis of K562, HepG2, and A549 cells in vitro.

In glioblastoma research, protodioscin significantly inhibited proliferation, induced mitochondrial dysfunction, and induced apoptosis of human glioblastoma cell lines. PD also enhanced autophagic activity, as indicated by upregulation of LC3B expression. In an in vivo glioblastoma xenograft model, PD treatment significantly suppressed tumor growth without affecting body weight or causing organ toxicity in PD-treated mice.

Protodioscin has a diverse pharmacological activity including neuroprotection, male fertility improvement, and cytotoxicity against various cancer cell lines of different origins. It is important to note that all anticancer evidence for protodioscin itself is currently confined to in vitro (cell culture) and animal (xenograft) studies. No human clinical trials of protodioscin as an anticancer agent have been published to date.

4.6 Anti-Hyperlipidemic Effects

In the context of phytotherapy, the furostanol saponin protodioscin has been studied for its anti-hyperlipidemic effect. Administration of protodioscin in hyperlipidemic rats significantly reduced the blood levels of triglycerides, cholesterol, and low- and high-density lipoproteins. This evidence remains at the preclinical (animal model) level; large, well-controlled human trials on protodioscin's anti-hyperlipidemic effects have not been published.

4.7 Neuroprotection

Animal research has investigated the potential neuroprotection of protodioscin against cerebral ischemia-reperfusion injury in rats through interventions in inflammation and apoptosis. This area of investigation is at an early, preclinical stage with no human data available.

4.8 Antiurolithiatic (Kidney Stone) Activity

The entire T. terrestris plant's phytochemical and phytopharmacological activities have been explored, including diuretic, anti-urolithiasis, anti-hypertensive, analgesic, anti-hyperlipidemic, immunomodulatory, antidiabetic, anticancer, anti-helminthic, aphrodisiac, antibacterial, hepatoprotective, and anti-inflammatory properties. The anti-urolithiatic evidence in humans is limited to traditional use and animal models.

5. Body Systems and Health Areas of Association

Reproductive and Endocrine System: Protodioscin is the main phytochemical compound in T. terrestris plants and is suggested to stimulate the production of testosterone in men, while women with hypoactive sexual desire disorder (HSDD) who received T. terrestris exhibited increased levels of testosterone.
Cardiovascular System: Because of its potassium-sparing, cardioprotective, and anti-hyperlipidemic properties, T. terrestris may have potential as herbal therapy for blood pressure control, according to the literature.
Urinary and Renal System: Traditional use in kidney stone prevention is widespread, though clinical evidence is limited, and paradoxical nephrotoxic effects have been reported in case reports (see Safety section).
Oncology (Preclinical): Protodioscin has been shown to exhibit anticancer, antimetastatic, and pro-autophagic and apoptotic activities in various malignant tumor cells in preclinical models.
Neurological System (Preclinical): Protodioscin has been investigated for neuroprotective potential in animal models of ischemia-reperfusion injury.
Musculoskeletal/Athletic Performance: Steroidal saponins from T. terrestris, like protodioscin, have been proposed to have beneficial effects on physical fitness through improvements in hemoglobin and hematocrit levels.
Immune System: Steroidal saponins contained in T. terrestris have demonstrated immunostimulant activity on macrophage activity in vitro assays and activation of non-specific immunity in animal models.

6. Dosage Forms and Reported Dosages

Protodioscin is administered almost exclusively as part of standardized plant extracts rather than as a purified isolated compound in commercial supplements. The following dosages are those reported in published studies and are reproduced here solely for informational accuracy.

Tribestan film-coated tablets containing 250 mg Tribulus terrestris dry extract (standardized to ≥112.5 mg furostanol saponins): administered as 3×2 tablets daily after meals during a 12-week clinical trial.
Furosap (fenugreek seed extract enriched in 20% protodioscin): 250 mg capsules twice daily (500 mg/day total), for 12 consecutive weeks, as used in a clinical evaluation of lean body mass and testosterone.
Supplementation doses administered in intervention studies varied from 450 mg to 2,700 mg daily of T. terrestris extract, with durations ranging from 20 days to 3 months.
In RCTs examining female sexual dysfunction, doses of 250–750 mg/day were used for 1–3 months of supplementation.
A 2021 RCT in CrossFit athletes used 770 mg/day of T. terrestris extract for 6 weeks.
In a preclinical pharmacodynamic study of methyl protodioscin, high intravenous dosage (80 mg/kg) had no serious side effects, with a clear pharmacokinetic/pharmacodynamic profile established in Traditional Chinese herbal medicine research.

7. Safety Considerations and Known Interactions

7.1 Gastrointestinal Effects

Transient gastrointestinal problems including irritation of gastric mucosa and gastric reflux have been associated with consumption of tribulus. These are among the most commonly reported adverse effects in clinical studies of T. terrestris preparations.

7.2 Hepatotoxicity

The steroidal saponin diosgenin is thought to be responsible for hepatotoxic effects associated with tribulus. Severe hyperbilirubinemia has been reported in a healthy 30-year-old male bodybuilder, followed by acute renal failure and bile-containing casts in the tubules, associated with the ingestion of tribulus extract tablets once daily for "a few months."

7.3 Nephrotoxicity and Neurotoxicity

A case of T. terrestris-induced hepatotoxicity, nephrotoxicity, and neurotoxicity was reported in an Iranian male patient who used the plant's extract to prevent kidney stone formation. He presented with seizure and very high serum aminotransferases and creatinine after consuming herbal water for 2 days. Discontinuation of the herbal remedy resulted in improvement in symptoms and normalization of his liver enzymes.

Neuro-, hepatic, and renal toxicity suggestive of acute tubular necrosis (ATN) was reported in a 28-year-old man who consumed large quantities of tribulus extract for its antiurolithiatic properties. Additionally, he developed hypertension, seizures, and markedly elevated serum aminotransferases (greater than 40 times the upper limit of normal).

Toxicological studies, although limited, have highlighted the risk of nephrotoxicity following administration of T. terrestris supplements.

7.4 Findings in Controlled Study Populations

None of the 165 men included in one systematic review suffered adverse effects during the T. terrestris supplementation protocol. No significant abnormal changes in renal function biomarkers were found. Therefore, no drug-induced nephrotoxicity or hepatotoxicity was reported in that particular group of studies. However, this is not consistent with other human clinical studies that have reported gastrointestinal problems such as stomach pain or gastric reflux, gynecomastia, priapism, nephrotoxicity, hyperbilirubinemia, hepatotoxicity, and neurotoxicity when taking T. terrestris.

7.5 Animal Toxicology

Acute oral toxicity study in rats established the median lethal dose (LD₅₀) of T. terrestris aqueous extract to be greater than 2,000 mg/kg body weight. No observed adverse effect level (NOAEL) was noted for repeated oral toxicity over 28 days at 750 mg/kg body weight.

Consumption of tribulus causes motor neuron adverse effects in animals by affecting the gamma-aminobutyric acid (GABA) receptors. This finding has been documented in livestock models; its relevance to human supplementation remains uncertain.

7.6 Bioavailability Considerations Affecting Safety Assessment

Studies have concluded that protodioscin had low bioavailability in vivo as a standalone compound; however, when administered as part of a whole plant extract from Dioscorea, the pharmacokinetic profile of protodioscin revealed good bioavailability. This variability in bioavailability depending on the matrix of the preparation has implications for both efficacy and toxicity assessments, since the pharmacologically active dose actually absorbed by the body may differ substantially depending on the extract type, preparation method, and co-constituents present.

7.7 Absence of Safety Data for Isolated Protodioscin

It is important to note that the overwhelming majority of both efficacy and safety data pertains to whole-plant extracts of T. terrestris or Dioscorea rather than to isolated protodioscin as a single compound. The extent to which adverse effects documented for T. terrestris extracts are attributable specifically to protodioscin — versus other saponins, alkaloids, or flavonoids present — has not been systematically established in published literature.

8. Evidence Strength Summary

Sexual function (male and female): Small RCTs and systematic reviews exist, but overall evidence certainty is rated as very low due to methodological limitations, small sample sizes, and inconsistent findings across trials.
Athletic performance / body composition: Human evidence does not consistently support benefit. Multiple studies found no significant effect on testosterone, body composition, or strength in healthy trained individuals.
Anticancer activity: Evidence is entirely preclinical (in vitro and animal xenograft models). No human clinical trials have been conducted.
Anti-hyperlipidemic effects: Evidence is limited to animal (hyperlipidemic rat) models. No human RCT evidence is available specifically for protodioscin.
Neuroprotection: Evidence is entirely preclinical (rodent ischemia-reperfusion models).
Safety: Controlled studies in healthy volunteers using standard doses have generally not reported serious adverse events, but case reports document serious hepatotoxicity, nephrotoxicity, and neurotoxicity associated with T. terrestris extracts in some individuals. A causal relationship specific to protodioscin has not been established.

References

Health Conditions

Health conditions that Protodioscin may help support.

Andropause (Male Hormonal Aging)Scientific
Protodioscin is the primary steroidal saponin in Tribulus terrestris responsible for its androgenic properties, documented to interact with androgen receptors and potentially enhance testosterone and DHEA production. It is found in multiple andropause-targeted plants (Tribulus, Dioscorea, Fenugreek) and is the active compound behind the libido, testosterone, and LH-stimulating effects attributed to these species.
Libido & Sexual Vitality (Men's)Scientific
Protodioscin is the principal steroidal saponin in Tribulus terrestris responsible for its pro-androgenic and pro-erectile effects. It may be converted to DHEA in the body and stimulates LH and testosterone synthesis. Used as the standardization marker for Tribulus extracts studied in clinical trials for male sexual function.

Body Systems

Body systems that Protodioscin may help support.

No body systems available.